Welcome to Mid-Market Central At Prime Therapeutics (Prime), we value our mid-market partner relationships and continually strive to create exceptional experiences for our customers. This resource...

A look at the specialty landscape and how Prime delivers value to employers

Diversity, equity and inclusion Our commitment to diversity, equity and inclusion (DEI) is rooted in our purpose and dedication to serving others. Breadcrumb Home Who we are Diversity, equity and...

publications Pancreatic cancer: Innovative therapy approved, but unmet need continues April 14, 2025 Author: Simone Ndujiuba, PharmD, BCOP In the United States, pancreatic cancer is the fourth...

Pat Gleason, assistant vice president, health outcomes, and David Eckwright, senior director, clinical project and program management, share an overview of Prime’s data and insights slated for this...

Eyebrow High-Cost Therapy Profile: February Detailed information about Marnetegragene autotemcel Intravenous (IV) High Cost Therapy Profile Gene Therapy/Immunology Marnetegragene autotemcel...

Breadcrumb Home Client Communication Pharmaceutical tariffs: Updates and featured news Pharmaceutical tariffs: Updates & news Your source for updates and featured client news on the evolving U.S....

Managed Markets Insight & Technology (MMIT)